Candriam S.C.A. Increases Position in Madrigal Pharmaceuticals, Inc. $MDGL

Candriam S.C.A. increased its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 32.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 84,948 shares of the biopharmaceutical company's stock after buying an additional 21,042 shares during the quarter. Candriam S.C.A. owned about 0.37% of Madrigal Pharmaceuticals worth $44,468,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in MDGL. Seelaus Asset Management LLC acquired a new stake in Madrigal Pharmaceuticals during the 1st quarter worth approximately $221,000. Greenwood Capital Associates LLC acquired a new position in shares of Madrigal Pharmaceuticals in the first quarter valued at approximately $357,000. Abel Hall LLC raised its stake in shares of Madrigal Pharmaceuticals by 79.0% during the first quarter. Abel Hall LLC now owns 1,271 shares of the biopharmaceutical company's stock worth $665,000 after purchasing an additional 561 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Madrigal Pharmaceuticals by 2.9% during the first quarter. Pictet Asset Management Holding SA now owns 187,240 shares of the biopharmaceutical company's stock worth $97,914,000 after purchasing an additional 5,291 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its holdings in shares of Madrigal Pharmaceuticals by 74.6% during the first quarter. Sterling Capital Management LLC now owns 213 shares of the biopharmaceutical company's stock worth $111,000 after purchasing an additional 91 shares during the period. Institutional investors and hedge funds own 98.50% of the company's stock.

Insider Transactions at Madrigal Pharmaceuticals

In related news, Director Richard S. Levy sold 5,682 shares of the firm's stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $515.44, for a total value of $2,928,730.08. Following the sale, the director directly owned 22,015 shares of the company's stock, valued at approximately $11,347,411.60. This trade represents a 20.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of Madrigal Pharmaceuticals stock in a transaction on Monday, June 1st. The shares were sold at an average price of $495.74, for a total transaction of $516,561.08. Following the completion of the transaction, the insider owned 10,033 shares in the company, valued at approximately $4,973,759.42. This trade represents a 9.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 7,568 shares of company stock valued at $3,880,711. 17.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MDGL. Piper Sandler reiterated an "overweight" rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, June 24th. HC Wainwright reiterated a "buy" rating and set a $620.00 target price on shares of Madrigal Pharmaceuticals in a research report on Wednesday, May 6th. Wells Fargo & Company raised Madrigal Pharmaceuticals to an "overweight" rating in a research note on Monday, June 1st. Bank of America cut their price objective on Madrigal Pharmaceuticals from $550.00 to $542.00 and set a "neutral" rating for the company in a research report on Thursday, June 11th. Finally, Truist Financial raised their target price on Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the company a "buy" rating in a report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Madrigal Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $687.93.

Madrigal Pharmaceuticals Price Performance

Shares of NASDAQ MDGL opened at $536.70 on Friday. The company has a current ratio of 3.50, a quick ratio of 3.16 and a debt-to-equity ratio of 0.63. The company's 50-day moving average price is $511.48 and its 200 day moving average price is $503.93. Madrigal Pharmaceuticals, Inc. has a 52 week low of $286.44 and a 52 week high of $615.00. The stock has a market cap of $12.38 billion, a price-to-earnings ratio of -41.93 and a beta of -1.05.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($3.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.61) by $0.36. Madrigal Pharmaceuticals had a negative net margin of 27.32% and a negative return on equity of 50.15%. The company had revenue of $311.34 million during the quarter, compared to analysts' expectations of $301.05 million. During the same quarter in the previous year, the business posted ($3.32) earnings per share. The firm's quarterly revenue was up 126.8% compared to the same quarter last year. As a group, research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -7.3 earnings per share for the current fiscal year.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company's pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.

Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.